
Fanfan Bao, Lin Sun, Weiying Guo Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of ChinaCorrespondence: Weiying Guo, Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of China, Email guowy@jlu.edu.cn; doctorweiyingguo@163.comAbstract: Polycystic ovary syndrome (PCOS) is a complex disorder of ovarian dysfunction primarily driven by a self-perpetuating pathophysiological cycle. This network centrally involves the interplay of insulin resistance (IR), hyperandrogenism, and obesity. IR stimulates ovarian and adrenal androgen production and can promote increased food intake. The resulting hyperandrogenemia, in turn, exacerbates insulin resistance and contributes to obesity. Furthermore, obesity worsens both IR and hormonal dysregulation through the release of inflammatory cytokines and adipokines, thereby reinforcing the entire cycle. This narrative review aims to critically examine the core pathological interplay between IR, hyperandrogenism, and obesity in PCOS. Building on this foundation, the review systematically explores the rationale and emerging evidence for novel therapeutic strategies that target these key components, moving beyond the established framework of current treatments. Lifestyle interventions, including dietary modification and physical activity, remain the cornerstone of PCOS management, particularly for overweight and obese patients. Current PCOS management primarily relies on oral contraceptives for symptomatic control of hyperandrogenism. Insulin-sensitizing agents form the other pillar of therapy. While metformin is widely used, newer classes of antidiabetic drug—including Dipeptidyl peptidase 4 inhibitors, sodium-glucose co-transporter protein 2 inhibitors, and glucagon-like peptide-1 receptor agonists—have demonstrated potential benefits that extend beyond glycemic control, offering improvements in weight, insulin sensitivity, and androgen levels. The discussion also extends to future perspectives, evaluating investigational approaches such as stem cell therapy and aldo-keto reductase 3 inhibitors, which, though not yet part of clinical practice, may represent future targeted treatment avenues. The management of PCOS is evolving from a symptomatic approach towards a more pathophysiologically-targeted and personalized strategy. A deep understanding of the IR-hyperandrogenism-obesity cycle is crucial for developing and implementing these novel therapies, which hold promise for improving long-term reproductive, metabolic, and cardiovascular outcomes for patients with PCOS. Future research should focus on validating these emerging treatments through robust clinical trials and defining their place within individualized treatment algorithms.Keywords: obesity, hyperandrogenism, insulin resistance, PCOS, therapy